全文获取类型
收费全文 | 307篇 |
免费 | 17篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 7篇 |
妇产科学 | 1篇 |
基础医学 | 47篇 |
临床医学 | 74篇 |
内科学 | 109篇 |
神经病学 | 31篇 |
特种医学 | 2篇 |
外科学 | 5篇 |
综合类 | 7篇 |
预防医学 | 16篇 |
药学 | 12篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 7篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 6篇 |
2015年 | 8篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 23篇 |
2011年 | 32篇 |
2010年 | 9篇 |
2009年 | 11篇 |
2008年 | 13篇 |
2007年 | 17篇 |
2006年 | 18篇 |
2005年 | 20篇 |
2004年 | 13篇 |
2003年 | 10篇 |
2002年 | 15篇 |
2001年 | 11篇 |
2000年 | 15篇 |
1999年 | 9篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 8篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1932年 | 2篇 |
1931年 | 2篇 |
1930年 | 1篇 |
1929年 | 1篇 |
1923年 | 2篇 |
排序方式: 共有325条查询结果,搜索用时 15 毫秒
1.
R. Gottschalk C. Seidl T. Löffler E. Seifried D. Hoelzer J.P. Kaltwasser 《Tissue antigens》1998,51(3):270-275
Abstract: Genetic hemochromatosis (GH) is closely associated with genes of the major histocompatibility complex (MHC) on chromosome 6. Recently, a candidate gene for GH, with structural similarities to MHC class I genes, designated HLA-H and presently named HFE, has been cloned. The HFE gene is localized telomeric to the MHC and several reports have indicated that the HFE gene is mutated in GH patients. In the present study we have analyzed the relationship of HFE gene variants and disease manifestation in GH patients and family members. Fifty-seven patients with GH, 73 family members and 153 healthy blood donors were studied for the amino acid dimorphism at codon 63 (His63Asp=H63D) and codon 282 (Cys282Tyr= C282Y) of the HFE gene. The codon 63 and 282 dimorphism were defined by PCR amplification of genomic DNA samples and restriction enzyme digestion using RsaI/SnaBI for C282Y and Bcll/Mbo 1 for H63D. Ferritin, transferrin serum levels and total iron-binding capacity were determined prior to therapeutic intervention. The Tyr-282 substitution occurred in 53 (93%) of patients compared with 8 (5.2%) of controls (OR=169, P >0.0001). Fifty-one (90%) patients were Tyr-282 homozygous. In contrast, the Asp-63 substitution was present in 5 (8.8%) of the patients compared with 34 (22%) of controls (OR=0.39, P =NS) with none of the patients being homozygous. In Tyr-282 homozygous GH patients serum ferritin levels, transferrin saturation, liver iron and liver iron index were elevated significantly compared to Tyr-282-negative patients, whereas no difference was observed between Tyr/Cys-282 heterozygous and Tyr-282-negative patients. 相似文献
2.
C. Seidl V. Brixner T. Müller-Kuller W. Sireis P. Costello Z. Cermakova F. Delaney A. M. Douglas M. Nightingale J. P. Van Galen M. O’Connell W. Siegel L. Sobaga J. De Wit E. Seifried 《ISBT科学丛刊》2008,3(1):54-62
The European blood legislation has defined several key quality elements to achieve Good Manufacturing Practice (GMP) in the field of blood transfusion. During the recent years, the blood legislation is in the process of implementation throughout its member states. Following the Directive 2002/98/EC, Directive 2005/62/EC has given further requirements for quality-management systems to be fulfilled by blood establishments. In addition, GMP/Good Laboratory Practice (GLP) and ISO standards are used inter alia by blood establishments. In order to support the implementation of the blood legislation, the European Public Health Work Plan (2005/2007) has cofunded two projects, led by the German Red Cross and supported by the European Blood Alliance, delivering a common European Standard Operating Procedure (SOP) methodology (EU-Q-Blood-SOP) and criteria and standards for the inspection of blood establishments (EUBIS). The EU-SOP manual will assist blood establishments in preparing for the inspection of their services related to the implementation of quality relevant elements required by the EU Directive 2002/98/EC and its technical annexes. The standards and criteria for inspection of blood establishments will cross-reference existing quality standards to the directive requirements and define requirements for the structure of quality-management systems based on the directive 2002/98/EC and its technical annexes. Based on these requirements, inspection standards and criteria are developed to assist in the independent assessment of quality systems established by individual blood establishments. These assessments are done in relation to the requirements defined by the European Union legislation on blood, in order to safeguard the quality of blood and to achieve continuous improvement of its quality throughout Europe. 相似文献
3.
G. Hunsmann J. Schneider H. Bayer R. Kurth A. Werner H. D. Brede V. Erfle W. Mellert H. R. Brodt L. Bergmann I. Helm I. Scharrer W. Kreuz H. Berthold P. Wernet E. M. Schneider K. Schimpf U. Egli U. Bienzle H. Schmitz P. Kern G. Krüger H. Rasokat E. Lechler E. Seifried P. Hellstern W. Schneider E. Holzer F. -D. Goebel R. Hehlmann 《Journal of molecular medicine (Berlin, Germany)》1985,63(5):233-235
Summary In 1984 10,281 sera were collected in the FRG and examined for antibodies to HTLV-III (LAV) with an enzyme-linked immunosorbent assay and confirmative tests. Of the German AIDS patients 81% have antibodies. Individuals belonging to AIDS risk groups, homosexuals, haemophiliacs and i.v. drug abusers, have antibody frequencies between 25%–72%. The detection of HTLV-III antibodies in blood donours indicates that the virus is being transmitted by blood transfusions.Abbreviations AIDS
acquired immunodeficiency syndrome
- LAS
lymphadenopathy syndrome
- ARC
AIDS related complex
- LAV
lymphadenopathy associated virus
- HTLV-III
human T-lymphotropic virus type III
- HBV
hepatitis B virus 相似文献
4.
J. Limmer D. Ellbrück H. Müller E. Eisele J. Rist F. Schütze H. Beger H. Heimpel E. Seifried 《Journal of molecular medicine (Berlin, Germany)》1994,72(11):913-919
A prospective, randomized, controlled clinical trial was performed comparing the antithrombotic efficacy of the low molecular weight heparin LMWH 21–23, (Braun) with an unfractionated heparin in elective general surgical patients over an observation period of 7 postoperative days. A total of 230 patients were admitted: 103 (group I) received low molecular weight heparin and 100 (group II) low-dose unfractionated heparin treatment given subcutaneously. In group I 41 patients (46%) were operated on for malignant disease and in group II 54 patients (54%). Due to the large amount of great abdominal procedures the intra- and perioperative application of hydroxyethyl starch was allowed for volume substitution. None of the patients died due to fatal pulmonary embolism. In group I four patients revealed positive 125I-labeled fibrinogen uptake (3.9%); two patients belonged to the hydroxyethyl starch subgroup. In group II five patients displayed a positive fibrinogen uptake (5%); two belonged to the hydroxyethyl starch subgroup. The results of the hemostaseological investigations (e.g., prothrombin time, activated partial thromboplastin time, thrombin clotting time, fibrinogen, antithrombin III, protein C, plasminogen, 2-antiplasmin , tissue-type plasminogen activator, plasminogen activator inhibitor) revealed no statistically significant differences between groups I and II or their subgroups, although a tendency to prolonged clotting times was observed. The antifactor Xa activity values, however, displayed a statistically significant difference between the two groups (P < 0.05). The antifactor Xa activity measured up to 0.16 U/ml for the low molecular weight heparin (group I) and 0.05 U/ml for the unfractionated heparin (group II) in the postoperative period. Major bleeding complications were not encountered in this study. Fundamental for the low incidence of thrombosis, the additive administration of hydroxyethyl starch appeared in almost one-third of the patients in both study groups.Abbreviations APTT
activated partial thromboplastin time
- aXa
anti-factor Xa
- DVT
deep venous thrombosis
- FUT
125I-labeled fibrinogen uptake test
- HES
hydroxyethyl starch
- LMWH
low molecular weight heparin
- PE
pulmonary embolism
- UFH
unfractioned heparin 相似文献
5.
Historical perspective: history of spinal surgery 总被引:5,自引:0,他引:5
The surgical treatment of spinal disorders did not develop before the 1970s of the last century. Previously limited technical possibilities and the danger of infections spinal surgery could not spread wider. This article reviews the history of spinal surgery from first trials as mentioned in the papyrus Smith in 1550 B.C. in Egypt to advanced techniques of today. 相似文献
6.
7.
Seventy-five unrelated hemophilia A patients from India were analyzed for factor VIII gene defects. Intron 22 inversion was identified in 22 patients and intron 1 inversion in 2 patients. In the remaining 51 patients without inversions screening the FVIII gene by denaturing high performance liquid chromatography (DHPLC) revealed 42 different mutations in 44 unrelated subjects. These included 14 missense, 7 nonsense, 9 splice site, 8 deletional, 3 insertional mutations and one indel mutation. Of these, 32 were novel gene alterations. The hotspots included intron 22 inversion, CpG and adenine runs. 相似文献
8.
Red blood cells treated with the amustaline (S‐303) pathogen reduction system: a transfusion study in cardiac surgery 下载免费PDF全文
Veronika Brixner Arndt‐Holger Kiessling Katharina Madlener Markus M. Müller Johannes Leibacher Sarah Dombos Iuliia Weber Hans‐Ulrich Pfeiffer Christof Geisen Michael Schmidt Reinhard Henschler Anne North Norman Huang Nina Mufti Anna Erickson Christine Ernst Salvador Rico Richard J. Benjamin Laurence M. Corash Erhard Seifried 《Transfusion》2018,58(4):905-916
9.
Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia 总被引:4,自引:0,他引:4
Koehl U Zimmermann S Esser R Sörensen J Grüttner HP Duchscherer M Seifried E Klingebiel T Schwabe D 《Bone marrow transplantation》2002,29(11):927-930
A pediatric patient with very early meningeal relapse of his CD34(+) CD133(-) pre-B-ALL was transplanted with 2.5 x 10(6)/kg CD133 selected autologous progenitor cells. Enrichment of CD133(+) cells resulted in a purity of 92.3 +/- 3.5% CD133(+). Hematopoietic engraftment with >1.0 x 10(9)/l neutrophils and >50 x 10(9)/l platelets was reached within 13 and 24 days, respectively. At a follow-up of 11(1/2) months after autologous transplantation, the patient is in complete remission. To our knowledge, the successful transplantation with a CD133 selected graft is the first one to be reported worldwide. CD133 selected cells may serve as an alternative in the case of CD34(+) malignancy. 相似文献
10.
Tacke F Schöffski P Trautwein C Martin MU Stangel W Seifried E Manns MP Ganser A Petersen D 《British journal of haematology》1999,105(2):511-513
Serum concentrations of the thrombopoiesis-enhancing cytokines thrombopoietin (TPO), erythropoietin (EPO), interleukin (IL)-6 and IL-11 were determined in 119 healthy whole-blood (WBD) and 101 platelet donors (PD) prior to donation. The 90% TPO reference interval in WBD of 64-867 pg/ml (median 163, 100% range 45-7572) was significantly higher than in PD of 56-524 (median 122, range 44-801, P = 0.004), whereas their platelet counts were lower (P < 0.001). EPO levels were not different (WBD 7.7 +/- 3.8, PD 8.0 +/- 4.9 IU/l), IL-6 and IL-11 were below the detection limit in >/=90% of cases (IL-6 < 3.2 pg/ml, IL-11 < 31.2 pg/ml). None of the cytokines correlated with platelet counts, other blood parameters, or in the PD group with the frequency of platelet donations within the last 6 months. We conclude that plateletpheresis does not lead to a lasting increase of thrombopoietic cytokines and provide reference data for potential platelet mobilization strategies with recombinant growth factors. 相似文献